Loading
In mice, losing the KDM6A gene turned pancreatic tumours squamous and metastatic, especially in females, by switching on growth regulators including MYC, and a drug class that blocks BET proteins reversed the change.
KDM6A, an X chromosome-encoded histone demethylase of the COMPASS-like complex, is frequently mutated across cancers. KDM6A loss induced squamous-like, metastatic pancreatic cancer selectively in females through deregulation of the COMPASS-like complex and aberrant activation of super-enhancers regulating delta-Np63, MYC and RUNX3. Tumours of this type in males had concomitant loss of UTY and KDM6A, pointing to demethylase-independent suppressor functions. KDM6A-deficient pancreatic cancer was selectively sensitive to BET inhibitors, which reversed squamous differentiation and restrained tumour growth in vivo.
It gives the 3 to 4% of KDM6A-mutant, squamous-programme tumours a mechanism and a candidate drug class.
Shares KDM6A, MYC, MYC, Pancreatic ductal adenocarcinoma.
Shares MYC, MYC, Pancreatic ductal adenocarcinoma.
Shares MYC, Epigenetic reprogramming.
Shares MYC, MYC, Epigenetic reprogramming.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/